Comparative Pharmacology
Head-to-head clinical analysis: APIDRA SOLOSTAR versus MERILOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APIDRA SOLOSTAR versus MERILOG.
APIDRA SOLOSTAR vs MERILOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glulisine is a recombinant human insulin analog that lowers blood glucose by binding to insulin receptors on muscle and fat cells, facilitating glucose uptake, and inhibiting hepatic glucose production.
Merilog is a recombinant human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Subcutaneous injection, 0.2-0.4 units/kg/day divided into two or more doses; for basal-bolus therapy, total daily dose is 0.5-1.0 units/kg/day with 50-60% as prandial insulin glulisine.
10 mg orally once daily, with or without food.
None Documented
None Documented
1.0-1.5 hours (terminal elimination half-life; consistent with rapid absorption and clearance; shorter than regular human insulin)
The terminal elimination half-life is approximately 18 hours, allowing for once-daily dosing in most patients. In renal impairment (CrCl <30 mL/min), half-life is prolonged to >40 hours, requiring dose adjustment.
Renal: 60-80% of dose as metabolites and parent drug; biliary/fecal: minor (20-40%)
MERILOG is primarily excreted renally as unchanged drug (85%) and as minor metabolites (10%). Fecal excretion accounts for less than 5%.
Category C
Category C
Insulin
Insulin